Krystal Biotech (NASDAQ:KRYS) Share Price Crosses Below Two Hundred Day Moving Average - Should You Sell?

Key Points

• KRYS fell below its 200-day moving average, trading as low as $281.40 and last changing hands at $295.90, down 11.0%.
• Krystal reported stronger-than-expected third-quarter results, with adjusted EPS of $2.05 and revenue of $127.34 million, driven by continued Vyjuvek strength. The company also authorized a $400 million share-repurchase program.
• Investor concerns include pipeline timelines shifting to 2027 and higher projected 2026 operating expenses of $155 million–$165 million. Despite mixed analyst views, the stock retains a “Moderate Buy” consensus with an average price target of $377.20.

Shares of Krystal Biotech, Inc. (NASDAQ:KRYS - Get Free Report) passed below its 200-day moving average during trading on Monday. The stock has a 200-day moving average of $308.70 and traded as low as $281.40. Krystal Biotech shares last traded at $295.90, with a volume of 1,203,533 shares changing hands.

Krystal Biotech News Roundup

Here are the key news stories impacting Krystal Biotech this week:

• Positive Sentiment: Krystal reported third-quarter adjusted EPS of $2.05, ahead of analyst estimates ranging from $1.79 to $1.92. Revenue reached $127.34 million, exceeding the $125.77 million consensus estimate and rising approximately 30% year over year. Krystal Biotech Surpasses Q3 Earnings and Revenue Estimates
• Positive Sentiment: Growth was driven by continued strength from Vyjuvek, Krystal’s commercial gene therapy for dystrophic epidermolysis bullosa. Management also announced a $400 million share-repurchase program expected to run over two years, which could support per-share results and signal confidence in the business. Krystal Biotech Beats on Vyjuvek Strength and Adds a Buyback
• Neutral Sentiment: Profitability remains strong, with a reported 54.82% net margin and 19.34% return on equity. However, EPS declined from $2.66 in the year-ago quarter, making continued revenue growth and pipeline execution important for maintaining the stock’s valuation. Krystal Biotech Third-Quarter Earnings Results
• Negative Sentiment: Investors appeared concerned that development timelines for Krystal’s pipeline programs have shifted into 2027. The company also revised its 2026 non-GAAP operating-expense outlook to $155 million-$165 million, raising questions about near-term spending and the timing of additional growth catalysts. Krystal Outlines Buyback and Revises Operating Expense Outlook

Wall Street Analyst Weigh In

KRYS has been the subject of a number of analyst reports. Zacks Research downgraded Krystal Biotech from a "hold" rating to a "strong sell" rating in a research report on Friday, October 23rd. Citigroup reaffirmed a "buy" rating on shares of Krystal Biotech in a report on Thursday, October 15th. Weiss Ratings raised shares of Krystal Biotech from a "buy (b-)" rating to a "buy (b)" rating in a report on Friday, October 23rd. Jefferies Financial Group reiterated a "buy" rating and issued a $474.00 price target on shares of Krystal Biotech in a research note on Monday, July 13th. Finally, Royal Bank Of Canada started coverage on shares of Krystal Biotech in a report on Friday, August 14th. They set an "outperform" rating and a $400.00 price target for the company. Two research analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $377.20.

Krystal Biotech Stock Down 11.0%

The stock has a market cap of $8.76 billion, a PE ratio of 37.08 and a beta of 0.50. The firm has a fifty day moving average of $336.45 and a 200 day moving average of $308.70.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last posted its quarterly earnings results on Monday, November 2nd. The company reported $2.05 earnings per share for the quarter, beating analysts' consensus estimates of $1.79 by $0.26. The company had revenue of $127.34 million for the quarter, compared to analysts' expectations of $125.77 million. Krystal Biotech had a return on equity of 19.34% and a net margin of 54.82%. On average, equities research analysts forecast that Krystal Biotech, Inc. will post 7.33 EPS for the current fiscal year.

Insider Transactions at Krystal Biotech

In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of the stock in a transaction that occurred on Friday, September 4th. The shares were sold at an average price of $359.32, for a total value of $8,983,000.00. Following the transaction, the insider directly owned 1,302,145 shares in the company, valued at $467,886,741.40. This represents a 1.88% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Dino Rossi sold 25,000 shares of the stock in a transaction on Friday, August 14th. The shares were sold at an average price of $329.12, for a total transaction of $8,228,000.00. Following the completion of the transaction, the director directly owned 50,000 shares in the company, valued at $16,456,000. This trade represents a 33.33% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Corporate insiders own 13.10% of the company's stock.

Hedge Funds Weigh In On Krystal Biotech

Several hedge funds have recently made changes to their positions in the company. Heritage Family Offices LLP purchased a new stake in shares of Krystal Biotech in the 3rd quarter valued at about $25,000. Silvant Capital Management LLC acquired a new stake in shares of Krystal Biotech in the 2nd quarter valued at about $30,000. Western Wealth Management LLC acquired a new stake in shares of Krystal Biotech in the 1st quarter valued at about $34,000. USA Financial Formulas purchased a new position in Krystal Biotech during the 1st quarter worth approximately $44,000. Finally, Integrated Wealth Concepts LLC purchased a new position in Krystal Biotech during the 2nd quarter worth approximately $46,000. Hedge funds and other institutional investors own 86.29% of the company's stock.

Krystal Biotech Company Profile

Krystal Biotech, Inc is a biotechnology company focused on developing and commercializing genetic medicines for rare diseases. The company's platform uses modified herpes simplex virus type 1 vectors to deliver functional genes to target tissues, with an emphasis on therapies that can be administered repeatedly.

Krystal's lead product, VYJUVEK, is a topical gene therapy for wounds associated with dystrophic epidermolysis bullosa, a rare inherited skin disorder caused by mutations affecting type VII collagen.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.